Back to User profile » Dr Lindsay GS Bengtson
Papers published by Dr Lindsay GS Bengtson:
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History
Sethi S, Clark B, Bengtson LG, Buysman EK, Palli S, Sargent A, Shaikh A, Ferguson GT
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:625-641
Published Date: 19 April 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
Hanania NA, Bunner SH, Bengtson LGS, Ismaila AS, Bogart M
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:407-418
Published Date: 24 March 2023
Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
Singer D, Bengtson LG, Elliott C, Buikema AR, Franchino-Elder J
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:3239-3250
Published Date: 7 December 2020
Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
Moretz C, Bengtson LGS, Sharpsten L, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2047-2060
Published Date: 4 September 2019
Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study
Moretz C, Sharpsten L, Bengtson LGS, Koep E, Le L, Tong J, Stanford RH, Hahn B, Ray R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:1721-1737
Published Date: 1 August 2019